Greenwich LifeSciences Collaborates with Unicancer for FLAMINGO-01 Expansion
Greenwich LifeSciences, Inc. (NASDAQ: GLSI), a pioneering clinical-stage biopharmaceutical firm, is making significant strides in cancer research by partnering with Unicancer to initiate clinical sites in France for its Phase III clinical trial, known as FLAMINGO-01. This innovative study aims to evaluate GLSI-100, an immunotherapy designed to prevent recurrences in breast cancer patients. The recent activation of these clinical sites underscores the commitment of Greenwich LifeSciences to enhance patient outcomes through advanced research.
The Urgent Need for Innovative Cancer Therapies
Breast cancer remains a prevalent health challenge in France, with new statistics revealing that it accounts for around 33% of all cancer diagnoses among women in the country. In 2022, 66,328 women were diagnosed with breast cancer, solidifying its status as the most frequently identified cancer. Tragically, this also includes 14,739 deaths attributed to breast cancer that same year. This urgent situation has propelled Greenwich LifeSciences to act, leveraging its expertise to tackle this significant health crisis.
Partnership with Unicancer
The collaboration with Unicancer, recognized as the largest academic breast cancer research network in France, will facilitate the activation of approximately 19 clinical sites within their extensive network. Following approval from French health authorities, the network’s clinical sites will undergo site initiation and training processes, with the aim of commencing operations 2025. Unicancer's dedication to oncology through its 18 Cancer Centers ensures a high level of patient care and research support.
Unicancer's Significant Contributions to Cancer Research
As the only hospital network fully devoted to cancer treatment in France, Unicancer plays a vital role in providing comprehensive care for nearly 530,000 patients every year. In addition to direct patient services, it sponsors numerous clinical trials, further establishing its reputation as a leading academic sponsor in oncology across Europe. Its commitment to research excellence, evidenced by over 700 clinical trials organized in 2020 alone, confirms its pivotal role in advancing cancer treatment methodologies.
Insights from Key Researchers
Dr. T. Bachelot, President of the Unicancer Breast Cancer Group (UCBG), expressed enthusiasm regarding the collaboration, stating, "Participation in the FLAMINGO study will help maintain our leadership in clinical research focused on cancer vaccination strategies." Meanwhile, Dr. F.C. Bidard, a critical figure in the FLAMINGO-01 Steering Committee, highlighted the innovative potential of anti-tumor vaccines like GLSI-100 in improving patient outcomes for those at high risk of relapse.
Advancing Cancer Treatment through Clinical Trials
The FLAMINGO-01 trial (NCT05232916) focuses on assessing the safety and efficacy of GLSI-100 among HER2 positive breast cancer patients. It represents a promising avenue for patients who have successfully undergone surgery. The design of the trial aims to provide key insights into the drug's potential benefits over traditional treatments, which is crucial for patients who are at significant risk of recurrence.
Future Implications and Company Vision
As part of its expansion strategy, Greenwich LifeSciences plans to establish up to 150 clinical trial sites globally, reflecting its commitment to widespread patient access and innovative cancer research. With a focus on immune-based therapies, the company endeavors to change the landscape of breast cancer treatment.
Frequently Asked Questions
What is the FLAMINGO-01 trial about?
The FLAMINGO-01 trial is a Phase III clinical study aimed at evaluating GLSI-100, an immunotherapy designed to prevent breast cancer recurrences in high-risk patients.
How many clinical sites will be involved in the trial?
Approximately 19 clinical sites in France will participate in the FLAMINGO-01 trial, all part of the Unicancer network.
What is the significance of partnering with Unicancer?
Unicancer is the largest academic breast cancer research network in France and brings extensive expertise and resources to the partnership, facilitating an efficient trial process.
How does GLSI-100 work?
GLSI-100 is an anti-tumor vaccine that promotes the immune system's response to prevent the recurrence of HER2 positive breast cancer.
What are the expected outcomes of the FLAMINGO-01 trial?
The trial aims to provide evidence of the safety and efficacy of GLSI-100, potentially improving treatment options for patients with a high risk of breast cancer recurrence.
